The earnings call reflects a strong financial performance with significant revenue growth and an optimistic future outlook. The primary growth drivers, RUCONEST and Joenja, have performed exceptionally well, and the upgraded revenue guidance underscores company confidence. However, challenges exist with the international market withdrawal of RUCONEST and the VUS reclassification timeline. Overall, the positive aspects outweigh the challenges.

Company Guidance

During Pharming Group N.V.'s third quarter 2025 conference call, the company provided updated guidance for the full year, raising its revenue expectations to between $365 million and $375 million, up from the previous range of $335 million to $350 million. This upward revision is driven by strong performance from its commercial assets, RUCONEST and Joenja, which reported year-over-year revenue growth of 29% and 35%, respectively. The company highlighted a significant increase in operating profit to $15.8 million, nearly four times the profit from the previous year. Additionally, operating cash flow reached $32 million, contributing to a cash position of $168.9 million by the end of the third quarter. Pharming also discussed strategic initiatives, such as the optimization of capital deployment and geographic expansion, which support its vision of becoming a leading global rare disease company.

Strong Revenue Growth

Total revenues grew by 30% in Q3 2025 compared to the same quarter last year, driven by RUCONEST and Joenja.

Operating Profit Surge

Operating profit increased to $15.8 million, nearly 4x last year's result.

Upgraded Revenue Guidance

Full year 2025 revenue guidance upgraded to $365 million - $375 million, up from $335 million - $350 million.

RUCONEST and Joenja Performance

RUCONEST revenue up by 29% and Joenja by 35% year-over-year.

Cash Flow and Position

Operating cash flow at $32 million, with cash and marketable securities increasing to $168.9 million.

Pipeline Progress

Advancements in pipeline including KL1333 for primary mitochondrial disease and potential for reclassification of APDS variants.

Pharming Group (PHAR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PHAR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 12, 2026	2025 (Q4)	0.02 / -	0.05	―	―	―
Nov 06, 2025	2025 (Q3)	<0.01 / 0.10	-0.02	600.00% (+0.12)
Jul 31, 2025	2025 (Q2)	-0.10 / 0.06	-0.02	400.00% (+0.08)
May 08, 2025	2025 (Q1)	-0.03 / -0.22	-0.19	-15.79% (-0.03)
Mar 13, 2025	2024 (Q4)	0.02 / 0.05	-0.04	225.00% (+0.09)
Oct 24, 2024	2024 (Q3)	>-0.01 / -0.02	0.005	-500.00% (-0.03)
Aug 01, 2024	2024 (Q2)	>-0.01 / -0.02	0.01	-300.00% (-0.03)
May 08, 2024	2024 (Q1)	<0.01 / -0.19	-0.17	-11.76% (-0.02)
Mar 14, 2024	2023 (Q4)	<0.01 / -0.04	-0.205	80.49% (+0.16)
Oct 26, 2023	2023 (Q3)	-0.13 / <0.01	0.4	-98.75% (-0.40)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PHAR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	$13.18	$14.70	+11.53%
Jul 31, 2025	$10.09	$11.11	+10.11%
May 08, 2025	$9.00	$10.01	+11.21%
Mar 13, 2025	$7.74	$8.74	+12.92%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Pharming Group Nv (PHAR) report earnings?

Pharming Group Nv (PHAR) is schdueled to report earning on Mar 12, 2026, Before Open (Confirmed).

What is Pharming Group Nv (PHAR) earnings time?

Pharming Group Nv (PHAR) earnings time is at Mar 12, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PHAR EPS forecast?

PHAR EPS forecast for the fiscal quarter 2025 (Q4) is 0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing